E&Y Report: Big Pharma Loses Edge As Big Biotech Provides More Competition For M&A Assets
This article was originally published in The Pink Sheet Daily
Big Pharma’s cash is still king, but its crown is slipping as its ability to fund M&A slows. Meanwhile, the smaller players in the industry are starting to make more high-value acquisitions and create more competition for pipeline assets.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.